glp-1 law firm / Ozempic James Boyd, a class action

8 Future directions The advancement of GLP-1 receptor agonists is progressing towards more refined treatment strategies, with tirzepatide at the forefront of research as a dual GIP/GLP-1 receptor agonist (Nauck and DAlessio 2022)

Specifically, understanding the role of GLP-1 and GLP-1RAs in the neurologic, and by extension, neuro-ophthalmic systems is of particular interest and the focus of this review

For Connecticut patients, the practical issue is not whether one medication has the most media attention

With weight gain, leptin levels rise, which causes the brain to send false signals of hunger, resulting in overeating

Approximately 10 weeks after discontinuation of BYDUREON therapy, plasma exenatide concentrations generally fall below the minimal detectable concentration of 10 pg/mL